RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Cash from operations

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 202497+95.75%
Dec 31, 202350-64.04%
Dec 31, 2022138+74.94%
Dec 31, 202179+44.36%
Dec 31, 202055-286.07%
Dec 31, 2019-29-115.12%
Dec 31, 2018194+107.40%
Dec 31, 201794+48.52%
Dec 31, 201663+50.98%
Dec 31, 201542+102.89%
Dec 31, 201421-3.59%
Dec 31, 201321+1910.56%
Dec 31, 20121-190.53%
Dec 31, 2011-1

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)